(Q39428554)

English

A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

Edith Blackburn

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Stefania Zona

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Mariana L Murphy

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Ian R Brown

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Samuel K W Chan

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

William J Gullick

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

15 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

134

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

53-59

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

The deaf and the dumb: the biology of ErbB-2 and ErbB-3

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

Green fluorescent protein as a tool to study epidermal growth factor receptor function

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

The upgraded role of HER3 and HER4 receptors in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1908-1

21 January 2018

Identifiers

10.1007/S10549-011-1908-1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39428554&oldid=2202872604"